Stage-Appropriate Quality Systems development comes up directly or indirectly in essentially all our client work. Quality Management is essential for emerging biopharma companies in particular, who face significant technical, scientific, clinical, and operational uncertainties. There is always a question of how much, and how soon?
We see some companies ‘build for success’ who then must pivot after experiencing a clinical or regulatory setback. We see other companies take a minimalist approach until PAI or even later.
Our latest Innovators Series webinar focused on this topic of how to design and construct a Stage-Appropriate Quality System. Experts discussed what the term means, and how to build a Quality System that fits their stage of growth and maturity.
Importance of a Stage-Appropriate Quality System
At our recent webinar, Melanie Cerullo from Arranta Bio discussed the current risk-based approach to cGMP and Quality, where the focus is on scientific approach to product quality (ICH Q8), risk management (ICH Q9) and integrated Quality Systems (ICH Q10). A company at any stage in the product development and commercialization lifecycle can apply these concepts (graphic courtesy of PDA).

She clearly articulated the interaction between cGMP and CMC. CGMP sets standards and practices for manufacturing, and CMC defines critical requirements and controls for your specific products and processes.
Converge’s CMC practice leader presented on Quality System evolution, highlighting how compliance is not the best route to Quality. He also drew important distinction between the appropriate evolution of Quality System controls for the more innovative treatments and processes we see in many of our emerging clients versus that required for traditional pharmaceutical development.